Evome Medical Technologies: New Appointments to the Board of Directors
New York, NY, March 17, 2025 – Evome Medical Technologies Inc. (EVMT), a leading innovator in the medical technology industry, is pleased to announce significant changes to its Board of Directors. These changes aim to strengthen the Company’s leadership team and further its mission to revolutionize healthcare through advanced technologies.
New Appointments
Michael Dalsin has been appointed as the new Chairman of the Board of Directors. Dalsin brings extensive experience in corporate leadership and strategic development, having served as the CEO of several successful companies in various industries. His expertise will be invaluable in guiding Evome through its growth phase.
Dr. Kenneth Kashkin will take on the role of Vice-Chairman. A renowned medical professional, Kashkin will provide strategic medical direction and contribute to the Company’s ongoing research and development efforts. His clinical knowledge and industry insights will be a crucial asset to Evome.
Bill Garbarini will continue his role as COO while stepping off the Board of Directors. Garbarini’s operational expertise and dedication have been instrumental in driving Evome’s success. He will remain an integral part of the Company’s executive team.
Chris Heath has been appointed as a new Director, increasing the size of the Board of Directors from five to six. Heath brings a wealth of experience in finance, marketing, and business development. His diverse skill set will significantly contribute to Evome’s growth and strategic initiatives.
Impact on the Individual
As a shareholder or potential investor, these appointments could have a positive impact on your investment. With a stronger leadership team in place, Evome is well-positioned to capitalize on opportunities in the medical technology industry. The addition of industry experts like Dalsin and Kashkin will further bolster the Company’s credibility and strategic direction.
Impact on the World
The medical technology sector is on the cusp of a major transformation, and Evome is at the forefront of this change. With the new appointments, the Company will be able to accelerate its research and development efforts, bringing innovative solutions to the healthcare industry. This could lead to improved patient outcomes, increased efficiency in healthcare delivery, and reduced costs. Ultimately, these advancements have the potential to change the way we approach healthcare and improve the lives of millions.
Conclusion
Evome Medical Technologies’ recent appointments to its Board of Directors mark an exciting new chapter for the Company. With the addition of industry experts and strategic leaders, Evome is poised to make a significant impact on the medical technology industry and the world at large. As a shareholder or potential investor, these developments provide a compelling reason to believe in Evome’s future success.
- Evome Medical Technologies announces new appointments to its Board of Directors
- Michael Dalsin appointed as Chairman
- Kenneth Kashkin becomes Vice-Chairman
- Bill Garbarini steps off the Board while retaining COO role
- Chris Heath joins as a new Director
- Appointments strengthen leadership team and further Evome’s mission
- Positive impact on shareholders and potential investors
- Advancements in medical technology have the potential to change healthcare and improve lives
